Table 4.
Unadjusted univariate Cox analysis
| Exposure | Statistics | Overall Survival |
|---|---|---|
| Risk Score | 1.80 ± 0.31 | 6.11 (2.01, 18.59) 0.0014 |
| Age | 63.84 ± 11.68 | 1.02 (0.99, 1.05) 0.1665 |
| Sex | ||
| Male | 44 (57.14%) | 1 |
| Female | 33 (42.86%) | 1.26 (0.71, 2.24) 0.4278 |
| Size (cm) | 3.70 ± 1.50 | 1.22 (1.01, 1.47) 0.0422 |
| KRAS mutation | ||
| Wildtype | 10 (12.99%) | 1 |
| Mutant | 67 (87.01%) | 1.21 (0.51, 2.86) 0.6593 |
| TP53 mutation | ||
| Wildtype | 25 (32.47%) | 1 |
| Mutant | 52 (67.53%) | 1.27 (0.68, 2.37) 0.4612 |
| CDKN2A mutation | ||
| Wildtype | 44 (57.14%) | 1 |
| Mutant | 33 (42.86%) | 1.87 (1.04, 3.36) 0.0362 |
| SMAD4 mutation | ||
| Wildtype | 56 (72.73%) | 1 |
| Mutant | 21 (27.27%) | 0.72 (0.37, 1.39) 0.3267 |
| BRCA1 mutation | ||
| Wildtype | 73 (94.81%) | 1 |
| Mutant | 4 (5.19%) | 4.06 (1.43, 11.53) 0.0086 |
| BRCA2 mutation | ||
| Wildtype | 75 (97.40%) | 1 |
| Mutant | 2 (2.60%) | 1.87 (0.45, 7.80) 0.3892 |
| Site | ||
| Head of Pancreas | 65 (84.42%) | 1 |
| Body and tail of Pancreas and others | 12 (15.58%) | 0.39 (0.14, 1.10) 0.0744 |
| Subtype | ||
| Pancreas-Adenocarcinoma Ductal Type | 69 (89.61%) | 1 |
| Pancreas-Adenocarcinoma-Other Subtype | 8 (10.39%) | 0.60 (0.22, 1.68) 0.3336 |
| Grade | ||
| G1 and G2 | 50 (64.94%) | 1 |
| G3 and G4 | 27 (35.06%) | 1.41 (0.79, 2.53) 0.2487 |
| T | ||
| T1 and T2 | 11 (14.29%) | 1 |
| T3 and T4 | 66 (85.71%) | 2.45 (0.87, 6.88) 0.0887 |
| N | ||
| N0 | 22 (28.57%) | 1 |
| N1 | 55 (71.43%) | 2.33 (1.12, 4.85) 0.0231 |
| AJCC stage | ||
| I | 8 (10.39%) | 1 |
| II and III | 69 (89.61%) | 1.63 (0.58, 4.57) 0.3547 |
| Residual tumor | ||
| R0 | 44 (57.14%) | 1 |
| R1 | 31 (40.26%) | 2.14 (1.17, 3.92) 0.0132 |
| R2 | 2 (2.60%) | 1.92 (0.25, 14.58) 0.5270 |
| Surgical treatment | ||
| Whipple | 65 (84.42%) | 1 |
| Distal Pancreatectomy | 9 (11.69%) | 0.55 (0.20, 1.54) 0.2520 |
| Others | 3 (3.90%) | 0.00 (0.00, Inf) 0.9971 |
| History of radiation therapy | ||
| No | 57 (74.03%) | 1 |
| Yes | 20 (25.97%) | 0.28 (0.12, 0.66) 0.0035 |
| History of targeted molecular therapy | ||
| No | 25 (32.47%) | 1 |
| Yes | 52 (67.53%) | 0.18 (0.10, 0.33) < 0.0001 |
| History of chemotherapy | ||
| No | 22 (28.57%) | 1 |
| Yes | 55 (71.43%) | 0.36 (0.20, 0.66) 0.0008 |
| Tobacco smoking history | ||
| Lifelong Non-smoker | 30 (38.96%) | 1 |
| Current or former smoker | 47 (61.04%) | 0.80 (0.44, 1.44) 0.4526 |
| Alcohol drinking history | ||
| No | 20 (25.97%) | 1 |
| Yes | 57 (74.03%) | 1.45 (0.74, 2.86) 0.2782 |
| History of chronic pancreatitis | ||
| No | 67 (87.01%) | 1 |
| Yes | 10 (12.99%) | 0.70 (0.30, 1.66) 0.4209 |
| History of diabetes | ||
| No | 57 (74.03%) | 1 |
| Yes | 20 (25.97%) | 0.51 (0.24, 1.10) 0.0849 |
| History of prior malignancy | ||
| No | 71 (92.21%) | 1 |
| Yes | 6 (7.79%) | 1.59 (0.56, 4.52) 0.3848 |